1. Home
  2. Scientists
  3. Kat Cole
Kat Cole at AG1

Kat Cole

Chief Executive Officer

Kat Cole is Chief Executive Officer and responsible for leading the company’s next phase of growth, global expansion, and innovation. Cole is a seasoned business leader and sought-after advisor with more than 20 years of operational, brand, and executive leadership experience.

Prior to AG1, she was President and COO at Focus Brands, where she oversaw the company’s nine presidents and businesses generating billions in sales around the world. In addition to her role at AG1, she serves on the boards of Slice and Milk Bar. She has been a Young Global Leader of the World Economic Forum, a member of the United Nations Global Entrepreneurs Council, and named to Fortune’s annual 40 Under 40 list.

Connect

Join Our Newsletter

© 2026 AG1

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Information on this site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Carefully read all product documentation. If you have or suspect that you have a medical problem, promptly contact your regular health care provider.

** AG1 Welcome Kit Offer valid for new AG1 subscribers only. AG1 Pro Welcome Kit included with the first AG1 Pro subscription order only. AGZ Frother Offer valid for first AGZ order only.

◊According to IQVIA Pro Voice Survey of 248 primary care physicians in December 2025.

††Free shipping on subscription purchases for new U.S. customers only.

  1. In a triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks using the AG1 Next Gen formula.
  2. In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37 using the AG1 Next Gen formula.
  3. In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome assessments of 40 healthy adults with occasional GI distress ages 26-59 over the course of 4 weeks using the AG1 Next Gen formula.
  4. In a double-blind, randomized, placebo-controlled crossover clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours using the AG1 Next Gen formula.
  5. In a third-party, single-arm, closed label interventional study of 104 healthy adults ages 25-59 assessing self-perceived efficacy of AG1 Next Gen over 3 months.

ΔTruemed eligibility and approval required. This link will take you to a third party website hosted by Truemed (the "Site"). Linking to this Site does not constitute an endorsement or approval by AG1 or any of its employees of the content, products, services or opinions on the Site. This is being provided as a convenience and AG1 bears no responsibility for the accuracy, legality or content of the Site or for that of any subsequent links on the Site. Contact the owners of the Site for answers to questions regarding its content.

Actual Packaging May Vary

Your privacy is our priority. Learn more: